Edition:
United States

People: Adaptimmune Therapeutics PLC (ADAP.OQ)

ADAP.OQ on NASDAQ Stock Exchange Global Select Market

3.27USD
19 Jul 2019
Change (% chg)

$-0.17 (-4.94%)
Prev Close
$3.44
Open
$3.45
Day's High
$3.45
Day's Low
$3.24
Volume
51,579
Avg. Vol
72,636
52-wk High
$14.52
52-wk Low
$3.20

Zaks, Tal 

Dr. Tal Zaks, M.D., Ph.D. has been appointed as Independent Non-Executive Director of the Company, with effect from November 14, 2016. He has served as the Chief Medical Officer of Moderna Therapeutics, Inc. since March 2015. He previously served as Senior Vice President and Head of Global Oncology at Sanofi Inc, where he was responsible for all aspects of oncology drug discovery, development and commercialization. Dr. Zaks began his industry career at GlaxoSmithKline in the genetics research group, where he built the oncology translational medicine team and led translational research on lapatinib as well as the in-licensing and clinical development of foretinib. In addition to his industry work, Dr. Zaks is an Adjunct Associate Professor of Medicine at the University of Pennsylvania and has served as a volunteer physician at the Philadelphia Veterans Administration Medical Center, treating patients with genitourinary cancers. Dr. Zaks received his M.D. and Ph.D. degrees from the Ben Gurion University in Israel and conducted post-doctoral research at the U.S. National Institutes of Health. He completed his clinical training in internal medicine at Temple University Hospital followed by a fellowship in medical oncology at the University of Pennsylvania.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --